Rakuten Aspyrian Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:$351.8M
Industry:Biotech
Founded:N/A
Lead Investor(s):SBI Group, Rakuten
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Rakuten Aspyrian's estimated revenue is currently $14.9M per year.
  • Rakuten Aspyrian received $134.0M in venture funding in December 2018.
  • Rakuten Aspyrian's estimated revenue per employee is $144466
  • Rakuten Aspyrian's total funding is $351.8M.

Employee Data

  • Rakuten Aspyrian has 103 Employees.
  • Rakuten Aspyrian grew their employee count by 102% last year.
  • Rakuten Aspyrian currently has 19 job openings.

Executive Contacts

NameTitle
Nate AsaroDirector Quality Assurance, GCP
Chris GallowayMedical Director
Jose LoboAssociate Director, Clinical Supplies
Carla HekmanDirector of Regulatory CMC and Technical Writing
Allen Anne-BarbaraDirector of Quality Assurance
Jessica BerrettDirector of Data Management
Lola FongDirector of Clinical Operations
Suzane SanDirector of People Operations
Eileen SunDirector Program Management
MIGUEL GARCIA-GUZMANchief scientific officer

What Is Rakuten Aspyrian?

Rakuten Aspyrian, Inc., is a privately funded clinical stage biotechnology company with offices in the USA, Japan and Germany. Since 2013, Rakuten Aspyrian has been developing new anticancer therapies based on the Photoimmunotherapy platform. Rakuten Aspyrian plans to become a fully integrated biopharma with research, development, and world-wide commercialization of therapies based on the Photoimmunotherapy platform. Our long-term objective is to commercialize a number of therapies based on Photoimmunotherapy to treat a broad range of solid tumor types as single agent and in combination with other immunomodulatory agents to generate robust and long lasting anticancer immunological responses. Rakuten Aspyrian is currently sponsoring a global Phase 3 multicenter clinical study for ASP-1929 to evaluate the efficacy and safety of ASP-1929 in patients with recurrent Head and Neck Cancer and additional Phase 2 studies to evaluate the safety and efficacy of ASP-1929 in patients with other cancer types. Given the rapid progression of the clinical studies, we are quickly expanding the team to support late stage pivotal clinical development and future commercialization of our products.

keywords:N/A

103

Number of Employees

$14.9M

Revenue (est)

19

Current Jobs

102%

Employee Growth %

$351.8M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
DiaCarta
$6.2M4310%$53M
Mission Bio
$10.7M7445%
Rigel Pharmaceu...
$42M2904%
ProTrials Resea...
$26.4M1823%
Trace Genomics
$5.9M4137%
Advanced Cell D...
$25.7M1788%
CellMax Life
$5.7M4011%$9M
Vaxart
$4.2M33-15%$58.6M
Full Spectrum A...
$6M425%
Calysta
$7.1M49-2%

Rakuten Aspyrian News

03/01/2019 - Rakuten Aspyrian Announces Name Change to Rakuten ...

SAN MATEO, Calif., March 1, 2019 /PRNewswire/ -- Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer ...

12/20/2018 - Rakuten Aspyrian Closes $284 Million Series C Financing for ...

SAN FRANCISCO, Dec. 20, 2018 /PRNewswire/ -- Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer ...

12/17/2018 - Rakuten Aspyrian Enrolling Phase 3 Trial of ASP-1929 for ...

SAN DIEGO, Dec. 17, 2018 /PRNewswire/ -- Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer therapies ...

Rakuten Aspyrian Funding

DateAmountRoundLead InvestorsReference
2018-08-24$150.0MCRakuten IncArticle
2018-12-21$134.0MCSBI GroupArticle

Rakuten Aspyrian Executive Hires

DateNameTitleReference
2018-11-15Mickey MikitaniCEO, chairmanArticle